FibroGen Inc
FGEN8.600USD
+0.280+3.37%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
34.79MMarket Cap
0.16P/E TTM
More Details of FibroGen Inc Company
FibroGen, Inc. is a biopharmaceutical company focused on the development of novel therapies at the frontiers of cancer biology and anemia. It is developing FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46, for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and potentially other cancers. This program also includes the development of FG-3180, an associated CD46-targeted positron emission tomography (PET) biomarker and imaging agent. It is also developing Roxadustat, an oral medication, first-in-class, oral small molecule hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), which is evaluated for the treatment of anemia in patients with chronic kidney disease (CKD), anemia associated with myelodysplastic syndromes and chemotherapy-induced anemia. Roxadustat is approved in China, Europe, Japan, and numerous other countries for the treatment of anemia of CKD in adult patients on dialysis (DD) and not on dialysis (NDD).
FibroGen Inc Info
Ticker SymbolFGEN
Company nameFibroGen Inc
IPO dateNov 14, 2014
CEOWettig (Thane)
Number of employees225
Security typeOrdinary Share
Fiscal year-endNov 14
Address350 Bay Street
CitySAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94133
Phone14159781200
Websitehttps://www.fibrogen.com/
Ticker SymbolFGEN
IPO dateNov 14, 2014
CEOWettig (Thane)
Company Executives of FibroGen Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Thane Wettig
Mr. Thane Wettig
Chief Executive Officer, Director
Chief Executive Officer, Director
24.28K
-1.06%
Mr. James A. (Jim) Schoeneck
Mr. James A. (Jim) Schoeneck
Independent Chairman of the Board
Independent Chairman of the Board
16.10K
+393.71%
Mr. David Delucia
Mr. David Delucia
Chief Financial Officer
Chief Financial Officer
4.39K
-1.17%
Mr. Jeffrey L. (Jeff) Edwards
Mr. Jeffrey L. (Jeff) Edwards
Independent Director
Independent Director
1.36K
+32.20%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
1.26K
+35.78%
Ms. Christine L. Chung
Ms. Christine L. Chung
Senior Vice President, China Operations
Senior Vice President, China Operations
--
--
Dr. Michael G. Kauffman, M.D., Ph.D.
Dr. Michael G. Kauffman, M.D., Ph.D.
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Thane Wettig
Mr. Thane Wettig
Chief Executive Officer, Director
Chief Executive Officer, Director
24.28K
-1.06%
Mr. James A. (Jim) Schoeneck
Mr. James A. (Jim) Schoeneck
Independent Chairman of the Board
Independent Chairman of the Board
16.10K
+393.71%
Mr. David Delucia
Mr. David Delucia
Chief Financial Officer
Chief Financial Officer
4.39K
-1.17%
Mr. Jeffrey L. (Jeff) Edwards
Mr. Jeffrey L. (Jeff) Edwards
Independent Director
Independent Director
1.36K
+32.20%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
1.26K
+35.78%
Ms. Christine L. Chung
Ms. Christine L. Chung
Senior Vice President, China Operations
Senior Vice President, China Operations
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
26.11M
88.16%
Europe
6.27M
21.17%
China
91.00K
0.31%
Japan - Related Party
-2.85M
-9.64%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Nov 18
Updated: Tue, Nov 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Armistice Capital LLC
9.34%
The Vanguard Group, Inc.
4.55%
Acadian Asset Management LLC
2.73%
BlackRock Institutional Trust Company, N.A.
2.08%
Marshall Wace LLP
1.79%
Other
79.51%
Shareholders
Shareholders
Proportion
Armistice Capital LLC
9.34%
The Vanguard Group, Inc.
4.55%
Acadian Asset Management LLC
2.73%
BlackRock Institutional Trust Company, N.A.
2.08%
Marshall Wace LLP
1.79%
Other
79.51%
Shareholder Types
Shareholders
Proportion
Hedge Fund
11.65%
Investment Advisor
9.61%
Investment Advisor/Hedge Fund
6.73%
Individual Investor
1.66%
Research Firm
0.22%
Other
70.14%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
188
1.07M
46.81%
--
2025Q3
214
1.07M
47.61%
-1.10K
2025Q2
269
1.07M
58.80%
-259.50K
2025Q1
333
1.37M
65.67%
-1.29M
2024Q4
342
1.49M
71.85%
-385.40K
2024Q3
352
1.88M
78.81%
-393.13K
2024Q2
365
2.27M
82.81%
-194.85K
2024Q1
367
2.47M
94.05%
-1.25M
2023Q4
366
2.82M
92.87%
+15.09K
2023Q3
380
2.80M
92.32%
-340.02K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Armistice Capital LLC
336.00K
8.31%
-4.00K
-1.18%
Jun 30, 2025
The Vanguard Group, Inc.
178.04K
4.4%
-56.33K
-24.03%
Jun 30, 2025
Acadian Asset Management LLC
139.12K
3.44%
-17.09K
-10.94%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
84.04K
2.08%
-9.02K
-9.69%
Jun 30, 2025
Marshall Wace LLP
72.30K
1.79%
-16.20K
-18.31%
Jun 30, 2025
PRIMECAP Management Company
89.70K
2.22%
-59.94K
-40.06%
Jun 30, 2025
Geode Capital Management, L.L.C.
44.04K
1.09%
+856.00
+1.98%
Jun 30, 2025
Two Sigma Investments, LP
14.11K
0.35%
-36.31K
-72.02%
Jun 30, 2025
Hightower Advisors, LLC
39.75K
0.98%
+23.57K
+145.65%
Jun 30, 2025
Renaissance Technologies LLC
11.18K
0.28%
-8.07K
-41.92%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Proshares Ultra Russell 2000
0%
Global X Aging Population ETF
0%
ProShares UltraPro Russell2000
0%
iShares Micro-Cap ETF
0%
ProShares Hedge Replication ETF
0%
Fidelity Enhanced Small Cap ETF
0%
Invesco RAFI US 1500 Small-Mid ETF
0%
Global X Russell 2000 ETF
0%
Global X Russell 2000 Covered Call ETF
0%
iShares Russell 2000 Value ETF
0%
View more
Proshares Ultra Russell 2000
Proportion0%
Global X Aging Population ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
iShares Micro-Cap ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Fidelity Enhanced Small Cap ETF
Proportion0%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Global X Russell 2000 Covered Call ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jun 12, 2025
Merger
25→1
Date
Type
Ratio
Jun 12, 2025
Merger
25→1
FAQs
Who are the top five shareholders of FibroGen Inc?
The top five shareholders of FibroGen Inc are:
Armistice Capital LLC holds 336.00K shares, accounting for 8.31% of the total shares.
The Vanguard Group, Inc. holds 178.04K shares, accounting for 4.40% of the total shares.
Acadian Asset Management LLC holds 139.12K shares, accounting for 3.44% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 84.04K shares, accounting for 2.08% of the total shares.
Marshall Wace LLP holds 72.30K shares, accounting for 1.79% of the total shares.
Armistice Capital LLC holds 336.00K shares, accounting for 8.31% of the total shares.
The Vanguard Group, Inc. holds 178.04K shares, accounting for 4.40% of the total shares.
Acadian Asset Management LLC holds 139.12K shares, accounting for 3.44% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 84.04K shares, accounting for 2.08% of the total shares.
Marshall Wace LLP holds 72.30K shares, accounting for 1.79% of the total shares.
What are the top three shareholder types of FibroGen Inc?
The top three shareholder types of FibroGen Inc are:
Armistice Capital LLC
The Vanguard Group, Inc.
Acadian Asset Management LLC
Armistice Capital LLC
The Vanguard Group, Inc.
Acadian Asset Management LLC
How many institutions hold shares of FibroGen Inc (FGEN)?
As of 2025Q4, 188 institutions hold shares of FibroGen Inc, with a combined market value of approximately 1.07M, accounting for 46.81% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.80%.
What is the biggest source of revenue for FibroGen Inc?
In FY2024, the -- business generated the highest revenue for FibroGen Inc, amounting to -- and accounting for --% of total revenue.
